第一型糖尿病 - VERTEX VX-880 臨床公布 1/2 期正向
2023.10.03 公布 VERTEX: VX-880 (摘要) VX-880 (T1D)療法皆是使用幹細胞衍生並且完全分化的胰島細胞 恢復胰島 B 細胞功能，恢復患者調節血糖能力 靜脈注射 All patients treated with VX-880 in Parts A and B have follow-up data beyond Day 90 and have demonstrated islet cell engraftment and glucose-responsive insulin production - All patients showed improvement across all measures of glucose control, including decreases in HbA1c, increases in blood glucose time-in-range, and reduction or elimination of insulin use -...